Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule.
The Food and Drug Administration (FDA) is issuing a final rule to amend its regulations to revise the Reye's syndrome warning required for oral and rectal over-the-counter (OTC) human drug products containing aspirin and to require a warning on OTC drug products containing nonaspirin salicylates as active ingredients. The revised warning will inform consumers of the symptoms of Reye's syndrome and advise that aspirin and nonaspirin salicylate drug products should not be given to children or teenagers who have or are recovering from chicken pox or flu-like symptoms. This final rule also finalizes FDA's notice of proposed rulemaking to require a Reye's syndrome warning for orally administered OTC drug products for relief of symptoms associated with overindulgence in food and drink (overindulgence drug products) that contain bismuth subsalicylate that published in the Federal Register of May 5, 1993 (58 FR 26886). FDA is issuing this final rule after considering public comment on the agency's notices of proposed rulemaking and all relevant data and information that have come to the agency's attention.
D000284:Administration, Oral; D000285:Administration, Rectal; D000293:Adolescent; D000930:Antidiarrheals; D001241:Aspirin; D002648:Child; D000075202:Contraindications; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006801:Humans; D007880:Legislation, Drug; D004366:Nonprescription Drugs; D012202:Reye Syndrome / Q000139:chemically induced*; D012459:Salicylates; D014481:United States; D014486:United States Food and Drug Administration
D000930:Antidiarrheals; D004366:Nonprescription Drugs; D012459:Salicylates; D001241:Aspirin